Medical Office Real Estate in San Francisco, CA

Cap rates for medical office properties in San Francisco vary by submarket, property class, and occupancy levels. The overall San Francisco market average cap rate is approximately 5.2%. Class A properties typically trade at lower cap rates than value-add opportunities.

Healthcare demand is driven by demographics (aging population) and medical necessity rather than economic conditions. People require medical care regardless of the economic environment, and the shift toward outpatient care continues to accelerate. Medical tenants have long lease terms, high renewal rates, and significant buildout costs that make relocation unattractive. These factors combine to produce stable occupancy and rent collection even during economic downturns.

On-campus MOBs are located on or immediately adjacent to a hospital campus, benefiting from direct referral traffic, shared services, and the hospital system brand. They typically command lower cap rates (4.5-5.5%) due to perceived stability. Off-campus MOBs are standalone or in medical parks away from hospitals, typically trading at higher cap rates (5.5-7.0%) but offering potentially higher returns. Off-campus properties may have more diverse tenant bases and less dependence on a single health system.

The San Francisco office market presents a classic contrarian opportunity. Vacancy rates and distressed pricing are at generational highs, and some properties are trading at 50-70% discounts to peak values. However, the recovery timeline is uncertain, and investors need to carefully evaluate building quality, location, and conversion potential. Trophy assets in prime locations with strong amenities are most likely to recover first.

Life sciences has been the standout sector in the Bay Area CRE market. Mission Bay, South San Francisco, and Emeryville have seen significant lab and R&D development driven by biotech company growth. While VC funding has moderated from 2021 peaks, the Bay Area's deep talent pool, research institutions (UCSF, Stanford, UC Berkeley), and established biotech ecosystem provide durable demand. New supply has increased vacancy, creating opportunities for well-located, purpose-built lab assets.